Alyeska Investment Group
ASMB icon

Alyeska Investment Group’s Assembly Biosciences ASMB Stock Holding History

Alyeska Investment Group’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,803
Closed -$803K – 363
2018
Q3 		$803K Buy
+1,803
New +$845K 0.01% 360

Other funds holding ASMB

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Alyeska Investment Group's ASMB Position: Q4 2018 in Review

Alyeska Investment Group sold out of Assembly Biosciences (ASMB) in Q4 2018, closing a stake of 1,803 shares — an estimated $803K sold.

Alyeska Investment Group first reported a position in ASMB in Q3 2018 and held it in 1 quarter. The position peaked at $803K in Q3 2018. 106 funds tracked by Wall St. Rank hold ASMB as of Q4 2018.

  • Alyeska Investment Group reported no remaining Assembly Biosciences position as of Q4 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 1,803 Assembly Biosciences shares in Q4 2018, an estimated $803K.
  • Alyeska Investment Group first reported a position in Assembly Biosciences in Q3 2018 and held it in 1 quarter.
  • Alyeska Investment Group's Assembly Biosciences position peaked at $803K in Q3 2018.
  • 106 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2018.

Based on Alyeska Investment Group's 13F filing for Q4 2018, filed 14 Feb 2019.